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Reducing serum low-density lipoprotein (LDL) cholesterol 
by statins has been shown to reduce cardiovascular events and 
mortality in secondary and primary prevention trials (1-3). 
Further reduction of serum LDL cholesterol in patients 
after an acute coronary syndrome treated with statins by 
ezetimibe (4) and in patients with cardiovascular disease 
treated with statins by the proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitor evolocumab (5) have been 
demonstrated to further reduce cardiovascular events .
Numerous epidemiological studies have demonstrated an 
inverse association between serum high-density lipoprotein 
(HDL) cholesterol levels and cardiovascular outcomes 
(6,7). However, randomized, placebo-controlled trials have 
not shown that increase of serum HDL cholesterol levels 
by drug therapy improves cardiovascular outcomes. In 
3,414 patients with cardiovascular disease receiving intensive 
statin therapy randomized to receive niacin or placebo, at 
2 years after therapy, niacin increased the median serum HDL 
cholesterol level from 35 to 42 mg/dL, reduced the serum 
LDL cholesterol level from 74 to 62 mg/dL, and reduced 
the serum triglyceride level from 164 to 122 mg/dL (8). 
At 3-year median follow-up, cardiovascular outcomes had 
occurred in 16.4% of patients treated with niacin versus 
16.2% of patients treated with placebo (8). In 25,673 patients 
with cardiovascular disease treated with statin therapy 
randomized to 2 grams of extended-release niacin-
laropiprant or placebo, at 3.9 years follow-up after therapy, 
compared with placebo, niacin-laropiprant increased serum 
HDL cholesterol by 6 mg/dL and reduced serum LDL 
cholesterol by 10 mg/dL (9). Compared with placebo, 
niacin-laropiprant did not reduce cardiovascular events but 
increased serious adverse events (9).
The cholesteryl ester transfer protein (CETP) inhibitors 
torcetrapib, dalcetrapib, evacetrapib, and anacetrapib 
inhibit the enzyme responsible for transferring cholesterol 
esters from HDL to very-low-density lipoprotein (VLDL) 
or LDL. These drugs have been shown to increase serum 
HDL cholesterol and reduce serum LDL cholesterol levels. 
However, at 15.1-year follow-up of 1,978 persons in the 
Framingham Heart Study, lower plasma CETP activity was 
associated with greater cardiovascular disease risk, which 
challenges the concept that CETP inhibition may lower 
cardiovascular disease risk (10). There are also conflicting 
data that genetic polymorphisms causing a lower mass or 
activity of CETP are associated with higher serum HDL 
cholesterol levels, lower serum LDL cholesterol levels, and 
a lower risk of coronary heart disease (11,12). 
The Investigation of  Lipid Level  Management 
to Understand its Impact in Atherosclerotic Events 
(ILLUMINATE) trial was a prospective randomized, 
double-blind study which randomized 15,067 patients, 
mean age 61.3 years, at high cardiovascular risk treated with 
atorvastatin to reduce the serum LDL cholesterol level to 
less than 100 mg/dL to receive torcetrapib 60 mg daily plus 
atorvastatin or atorvastatin only (13). At 12-month follow-up, 
torcetrapib increased serum HDL cholesterol 72.1% 
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and reduced serum LDL cholesterol 24.9%. However, 
torcetrapib also increased systolic blood pressure by 
5.4 mm Hg and caused a decrease in serum potassium and 
an increase in serum sodium, bicarbonate, and aldosterone 
levels. At a median follow-up of 550 days, the primary 
outcome of time to death from coronary heart disease, 
nonfatal myocardial infarction, stroke, or hospitalization 
for unstable angina pectoris was increased 25% (95% CI, 
9% to 44%; P=0.001) by torcetrapib (13). Torcetrapib also 
increased all- cause mortality by 58% (95% CI, 1.14 to 
2.19; P=0.006) (13). The off-target pharmacologic effects 
contributed to the increase in cardiovascular events and 
in all-cause mortality. It has also been suggested that 
CETP inhibition may cause HDL particles which are 
nonfunctional or even proatherogenic (14). Recent data 
showed that torcetrapib increased the HDL subclasses 
LpA-I and LpA-II equally and the apoC-III content of 
HDL without affecting the apoB-containing subclasses, 
supporting that the adverse effects of torcetrapib were not 
due to disturbances in lipoprotein transport (15). 
The effects of dalcetrapib in patients with a recent 
acute coronary syndrome (dal-OUTCOMES ) study 
randomized 15,871 patients, mean age 60.2 years, with 
a recent acute coronary syndrome to receive the CETP 
inhibitor dalcetrapib 600 mg daily or to receive placebo (16). 
Statins were used in 98% of patients at the time of 
randomization. At the time of randomization, the mean 
serum HDL cholesterol level was 42 mg/dL, and the mean 
serum LDL cholesterol level was 76 mg/dL. During the 
study, the serum HDL cholesterol level increased from 
baseline by 4% to 11% in the placebo group and by 31% 
to 40% in the group treated with dalcetrapib. Dalcetrapib 
caused a minimal effect on serum LDL cholesterol levels. 
Compared with placebo, dalcetrapib increased the median 
C-reactive protein level by 0.2 mg/L and the mean systolic 
blood pressure by 0.6 mmHg. At a median follow-up of 
31  months ,  compared wi th  p lacebo,  da lcetrapib 
insignificantly increased the primary endpoint of death 
from coronary heart disease, nonfatal myocardial infarction, 
ischemic stroke, unstable angina pectoris, or cardiac arrest 
with resuscitation by 4% (16). 
The Randomized Evaluat ion of  the Effects  of 
Anacetrapib through Lipid-modification (REVEAL) trial is 
an ongoing trial of 30,449 patients, mean age 67 years, with 
cardiovascular disease being treated with atorvastatin for an 
average of at least 4 years who were randomized to receive 
the CTEP inhibitor anacetrapib 100 mg daily or to receive 
placebo (17). At the time of randomization, the mean 
plasma HDL cholesterol was 40 mg/dL, and the mean 
plasma LDL level was 61 mg/dL. Results are anticipated in 
2017 (17). 
This editorial was written to discuss the results of the 
recently published paper on the Assessment of Clinical 
Effects of Cholesteryl Ester Protein Inhibition with 
Evacetrapib in Patients at a High Risk for Vascular Outcomes 
(ACCELERATE) trial (18). This study was a multicenter, 
randomized , double-blind, placebo-controlled phase3 
trial which included 12,092 patients, mean age 64.9 years 
(46.5% men), who had at least one of the following medical 
conditions: an acute coronary syndrome within the prior 30 to 
365 days (30.2%), cerebrovascular atherosclerotic disease 
(11.9%), peripheral vascular arterial disease (13.9%), or 
diabetes mellitus with coronary arterial disease (64.4%) (18). 
Statins were used to treat 96.5% of the patients. 
Antihypertensive drug therapy was used to treat 87.3% of 
the patients. The baseline serum HDL cholesterol level 
was 45.3 mg/dL, LDL cholesterol level was 81.4 mg/dL, 
and triglycerides was 128 mg/dL. The patients were 
randomized to receive evacetrapib 130 mg daily or to 
receive matching placebo. The primary efficacy endpoint 
was the first occurrence of any component of the composite 
of cardiovascular death, myocardial infarction, stroke, 
coronary revascularization, or hospitalization for angina 
pectoris. At 3 months, the mean serum HDL cholesterol 
was increased by 133.2% with evacetrapib and by 1.6% 
with placebo, and the mean serum LDL cholesterol level 
was reduced by 31.1 % with evacetrapib and increased by 
6.0% with placebo. At a median follow-up of 26 months, 
a primary end point event occurred in 12.9% of patients 
treated with evacetrapib versus in 12.8% of patients treated 
with placebo (18).
These data demonstrated that evacetrapib significantly 
increased serum HDL cholesterol and significantly reduced 
serum LDL cholesterol. However, despite these favorable 
effects on serum HDL cholesterol and on serum LDL 
cholesterol, evacetrapib did not reduce cardiovascular 
events in patients with high-risk cardiovascular disease (18).
There is a large body of data from animal intervention 
studies and from human genetic studies supporting that 
CTEP inhibition is antiatherogenic and, therefore, will 
reduce cardiovascular events in humans (19). However, the 
lack of consistent data about the consequences of genetically 
defined CTEP deficiency, the variability in lipid parameters 
in patients treated with the different CETP inhibitors, 
and the negative clinical outcomes of the clinical trials 
reported support that lowering of CTEP will not reduce 
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cardiovascular events (20).
The results from the ILLUMINATE trial (13), the 
dal-OUTCOMES trial (16), and the ACCELERATE 
trial (18) support that CTEP inhibition will not reduce 
cardiovascular events in humans. We are awaiting the 
clinical outcome data from the REVEAL trial to know 
whether or not the CETP inhibitor anacetrapib will reduce 
cardiovascular events.
Data from the niacin trials (8,9) and from the 3 
completed large-scale CTEP inhibitor trials (13,16,18) have 
clearly demonstrated that raising serum HDL cholesterol 
does not improve cardiovascular outcomes. Future HDL 
cholesterol trials may need to measure HDL subclasses and 
HDL functionality (21). A low HDL cholesterol level may 
only be a marker of cardiovascular disease. Increasing HDL 
cholesterol so far by pharmacologic therapy has not been 
shown to reduce cardiovascular events. Although lowering 
serum LDL cholesterol by statins (1-3) ezetimibe (4), 
and the PCSK9 inhibitor evolocumab (5) have been 
demonstrated by large-scale clinical trials to reduce 
cardiovascular events, reducing serum LDL cholesterol by 
niacin (8,9), torcetrapib (13), and by evacetrapib (18) have 
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